Management of the patient and family with neurofibromatosis 2: a consensus conference statement.
A consensus conference on neurofibromatosis 2 (NF2) was held in 2002 at the request of the United Kingdom (UK) Neurofibromatosis Association, with particular emphasis on vestibular schwannoma (VS) surgery. NF2 patients should be managed at specialty treatment centres, whose staff has extensive experience with the disease. All NF2 patients and their families should have access to genetic testing because presymptomatic diagnosis improves the clinical management of the disease. Some clinical manifestations of NF2, such as ocular abnormalities, can be detected in infancy; therefore, clinical screening for at-risk members of NF2 families can start at birth, with the first magnetic resonance (MRI) scan at 10-12 years of age. Minimal interference, maintenance of quality of life, and conservation of function or auditory rehabilitation are the cornerstones of NF2 management, and the decision points to achieve these goals for patients with different clinical presentations are discussed.
Evans
D G R
DG
Department of Medical Genetics, St Mary's Hospital, Manchester, UK. Gareth.Evans@CMM.nhs.uk
Baser
M E
ME
O'Reilly
B
B
Rowe
J
J
Gleeson
M
M
Saeed
S
S
King
A
A
Huson
S M
SM
Kerr
R
R
Thomas
N
N
Irving
R
R
MacFarlane
R
R
Ferner
R
R
McLeod
R
R
Moffat
D
D
Ramsden
R
R
D000328:Adult; D003937:Diagnosis, Differential; D005192:Family Health; D006801:Humans; D016518:Neurofibromatosis 2 / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D009464:Neuroma, Acoustic / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D010348:Patient Care Team